1. Home
  2. COP vs VRTX Comparison

COP vs VRTX Comparison

Compare COP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConocoPhillips

COP

ConocoPhillips

HOLD

Current Price

$115.91

Market Cap

136.5B

Sector

Energy

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$441.69

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
COP
VRTX
Founded
1917
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Integrated oil Companies
EDP Services
Sector
Energy
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
136.5B
115.7B
IPO Year
2005
2006

Fundamental Metrics

Financial Performance
Metric
COP
VRTX
Price
$115.91
$441.69
Analyst Decision
Buy
Buy
Analyst Count
22
29
Target Price
$123.59
$539.69
AVG Volume (30 Days)
8.5M
1.2M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
2.76%
N/A
EPS Growth
N/A
836.54
EPS
6.35
15.32
Revenue
$58,944,000,000.00
$2,488,652,000.00
Revenue This Year
$6.88
$10.81
Revenue Next Year
N/A
$10.41
P/E Ratio
$19.12
$28.46
Revenue Growth
7.67
46.20
52 Week Low
$84.28
$362.50
52 Week High
$135.87
$510.77

Technical Indicators

Market Signals
Indicator
COP
VRTX
Relative Strength Index (RSI) 38.24 45.77
Support Level $89.51 $427.52
Resistance Level $122.50 $442.22
Average True Range (ATR) 3.91 10.31
MACD -2.01 0.72
Stochastic Oscillator 16.02 57.31

Price Performance

Historical Comparison
COP
VRTX

About COP ConocoPhillips

ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: